(Stroke. 1998;29:2461-2466.)
© 1998 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Correspondence to Stefan Schwab, MD, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail Stefan_Schwab{at}ukl.uni_heidelberg.de
| Abstract |
|---|
|
|
|---|
MethodsModerate hypothermia was induced in 25 patients with severe ischemic stroke in the middle cerebral artery (MCA) territory for therapy of postischemic brain edema. Hypothermia was induced within 14±7 hours after stroke onset and achieved by external cooling with cooling blankets, cold infusions, and cold washing. Patients were kept at 33°C body-core temperature for 48 to 72 hours, and intracranial pressure (ICP), cerebral perfusion pressure, and brain temperature were monitored continuously. Outcome at 4 weeks and 3 months after the stroke was analyzed with the Scandinavian Stroke Scale (SSS) and Barthel index. The side effects of induced moderate hypothermia were analyzed.
ResultsFourteen patients survived the hemispheric stroke (56%). Neurological outcome according to the SSS score was 29 (range, 25 to 37) 4 weeks after stroke and 38 (range 28 to 48) 3 months after stroke. During hypothermia, elevated ICP values could be significantly reduced. Herniation caused by a secondary rise in ICP after rewarming was the cause of death in all remaining patients. The most frequent complication of moderate hypothermia was pneumonia in 10 of the 25 patients (40%). Other severe side effects of hypothermia could not be detected.
ConclusionsModerate hypothermia in the treatment of severe cerebral ischemia is not associated with severe side effects. Moderate hypothermia can help to control critically elevated ICP values in severe space-occupying edema after MCA stroke and may improve clinical outcome in these patients.
Key Words: hypothermia intracranial pressure neuroprotection outcome stroke, ischemic treatment
| Introduction |
|---|
|
|
|---|
The mechanisms by which hypothermia is neuroprotective are not fully understood yet. Hypothermia, however, was found to reduce cerebral metabolism, decrease levels of excitatory amino acids, stabilize the blood-brain barrier, and account for membrane stabilization and the decrease in heat shock proteins after induced brain injury.10 11 12
Several clinical studies reported the effects of hypothermia in the therapy of traumatic brain injury.13 14 15 16 All demonstrated that mild to moderate hypothermia has the potential to limit the extent of secondary brain injury and may be effective in the treatment of patients with severe traumatic head injury.
Even though hypothermia has potent cerebroprotective effects after experimental focal ischemia, clinical studies on hypothermic therapy after middle cerebral artery (MCA) infarction are not available. However, 2 recent clinical studies emphasized the importance of body temperature for stroke prognosis and severity.17 18 Reith et al18 demonstrated lower mortality and better outcome in patients with mild hypothermia (<36.5°C) on admission. Azzimondi et al17 showed that fever in the first 7 days after stroke was an independent predictor of poor outcome.
We performed an open pilot study on the efficacy, feasibility, and safety of induced moderate hypothermia in the therapy of patients with acute, severe MCA infarction and increased intracranial pressure (ICP).
| Subjects and Methods |
|---|
|
|
|---|
The ICP was monitored in all patients with 2 different types of intraparenchymatous sensors and transducers (Spiegelberg pneumatic transducer, Spiegelberg AG, n=16; Codman microsensor, Johnson & Johnson, n=9). ICP devices were inserted ipsilaterally to the affected hemisphere in 18 patients and bilaterally in 7 patients. Clinical data were obtained daily from all patients and assessed with the Scandinavian Stroke Scale (SSS) and Glasgow Coma Scale (GCS).19 20 Clinical outcome was assessed 4 weeks and 3 months after stroke with the 58-point SSS and the Rankin scale. Daily living activities were rated with the 100-point Barthel index (BI).21 22
General Critical Care
The focus of critical care for all patients was to maintain
cerebral perfusion pressure (CPP) above 70 mm Hg. CPP was
calculated as the difference between mean arterial blood
pressure and ICP. To reach mean arterial blood levels
>90 mm Hg, vasopressors (norepinephrine 0.2
µg · kg-1 ·
min-1) were used. Hemoglobin concentration was
maintained at >90 g/L. Patients with increased ICP (>20 mm Hg)
were treated with intermittent boluses of mannitol (0.5 to 1 g/kg)
before initiation of hypothermia. Hyperventilation or barbiturates were
not part of our treatment regimen. In 7 patients, an optimetric jugular
bulb catheter for cerebrovenous oxygen saturation monitoring (Opticath,
Abbott Laboratories) was inserted. Monitoring in the
neurocritical care unit always consisted of continuous monitoring of
ICP, CPP, ECG, end-expiratory PCO2,
and blood pressure. We adjusted ventilatory parameters to a
PO2 of >90 mm Hg and a
PCO2 between 35 and 40 mm Hg
(ie, by increasing positive end-expiratory pressure or
FiO2).
Temperature Protocol
Brain temperature was measured with the Spiegelberg
intraparenchymatous ICP probe, which has a thermistor in its tip.
Accuracy for temperature measurements is <0.1°C. A Foley temperature
catheter for bladder temperature reading with a temperature resolution
of 0.1°C was used for monitoring body-core temperature (Mon-a-therm,
Mallinckrodt). All patients were sedated with fentanyl and propofol and
received neuromuscular blockade with continuous infusion of atracurium
(0.3 to 0.6 mg/kg IV).
Room temperature in the intensive care unit was between 18°C and
20°C. In this study, a cooling blanket (Polar Bair, Augustine
Medical) with cool ventilator air fanning the patient's body surface
was used for external cooling. Acid-base management was guided by
blood-gas analysis not corrected for temperature to maintain
autoregulation (
-stat management).23 Once the body-core
temperature reached 33°C, it was kept between 33°C and 34°C for
48 to 72 hours. During the next 24 hours, the patient was passively
rewarmed to a normal temperature.
Evaluation of Side Effects
Side effects known to be related to hypothermia, such as
infections, coagulation disorders, and decreased cardiac
performance with bradycardia, cardiac arrhythmia, and
hypotension, were documented and analyzed. Sepsis as a systemic
response to infection was suspected, according to the criteria of the
American College of Chest Physicians, when
2 of the following
conditions became manifest: heart rate >90 bpm, white blood cell count
>12 000 or <4000 cells/mm3, respiratory rate
>20 breaths per minute, or PaCO2
<32 mm Hg. Body temperature as 1 further point was not
analyzed.24 Pneumonia was suspected if the
following criteria were met: new infiltrates on chest x-ray, purulent
tracheobronchial secretions, and impairment of pulmonary gas
exchange. Renal function was evaluated by urine output and
creatinine clearance. Activated prothrombin and
partial thromboplastin times were measured every 6 hours to evaluate
intrinsic and extrinsic coagulation pathways. Platelet counts,
serum enzymes, and electrolytes were determined every 12 hours.
Statistics
All values are expressed as mean±SD. Median is also given for
ordinal data, such as SSS and BI. Physiological
measurements within groups were analyzed by
nonparametric tests as appropriate (Wilcoxon
signed-rank test). Significance was assigned at
P<0.05.
| Results |
|---|
|
|
|---|
|
Mean interval between onset of symptoms of ischemic stroke and
initiation of hypothermia was 14 hours (range, 4 to 24 hours). Time
required for cooling to 33°C bladder temperature was from 3.5 to 6.2
hours. Moderate hypothermia was sustained for 48 to 72 hours (median,
65 hours). Passive rewarming took between 17 and 24 hours (median, 18
hours). The monitoring device was inserted at a mean of 10 hours after
stroke onset (range, 6 to 32 hours), and the average ICP monitoring
period varied between 3 and 7 days (mean, 4.9±2.5 days). Mean initial
ICP was 20.9±12.4 mm Hg (range, 13 to 36 mm Hg). In all
patients, ICP values decreased with initiation of moderate hypothermia
to mean values of 14.5±4.2 mm Hg. When the steady state of
hypothermia was reached, ICP values were 13.4±8.3 mm Hg, which
was significantly lower than initial values (P<0.05).
During rewarming, ICP values rose continuously; the highest measured
mean values were 19.4±8.7 mm Hg (range, 17 to 52 mm Hg).
In the group of patients who died, mean ICP values were 22±12.6
mm Hg (range, 20.4 to 52 mm Hg). Mean initial CPP was 68
mm Hg (range, 60 to 85 mm Hg). After induction of moderate
hypothermia, mean CPP was 78 mm Hg (range, 65 to 90 mm Hg)
(P<0.05). After rewarming, CPP varied between 60 and
90 mm Hg (mean, 70 mm Hg). Eighteen patients received
vasopressors to maintain CPP values >70 mm Hg after rewarming
(Table 2
).
|
In all patients, intraparenchymatous brain temperature before initiation of hypothermia exceeded body-core temperature, with a mean of 1.5±0.3°C (range, 1.0°C to 2.1°C). The difference between brain and body-core temperatures varied individually and over the measurement period. Hence, the difference between brain and body-core temperatures was independent of ICP or CPP. With induction of moderate hypothermia, the temperature gradient between body core and brain decreased by a mean of 0.3±0.4°C (range, -0.3°C to 1.0°C).
All 14 patients who survived their severe strokes were discharged to rehabilitation programs. Their neurological outcome according to the SSS score 4 weeks after stroke was 29 (range, 25 to 37). Three months after stroke, SSS was 38 (range, 28 to 48); w 1 patient died of a pulmonary embolus. The median BI of the surviving patients was 70 (range, 60 to 85), and the mean Rankin scale was 2.6 (range, 2 to 4).
Side Effects
Before initiation of hypothermia, a systemic response to infection
was absent in all 25 patients, whereas after rewarming, 7 patients had
a septic syndrome according to the above-mentioned criteria. The most
frequent complication of moderate hypothermia was pneumonia, which was
encountered in 10 of the 25 patients (40%). In 6 patients, pneumonia
was diagnosed during rewarming. Activated prothrombin and
partial thromboplastin times remained unchanged during hypothermia.
However, platelet count decreased significantly during hypothermia
and was lower than initial values. This effect lasted up to 3 days
after rewarming. The observed thrombopenia was asymptomatic
and did not cause any bleeding complications. Urine output and
creatinine clearance did not demonstrate a statistically
significant difference before, during, or after induction of
hypothermia. A significant increase in serum amylase and lipase in 7 of
the 25 patients (28%) with maximal lipase levels of 1200 U/L (normal
value, <150 U/L) occurred under hypothermic therapy. However, there
were no clinical signs and symptoms of acute pancreatitis in any
patient. Analysis of serum sodium concentrations remained
unchanged during hypothermia, but serum potassium concentrations were
markedly decreased during cooling and in the steady state of
hypothermia. Cardiac arrhythmias (with prolongation of the PR
and QT intervals) and sinus bradycardia were seen in 15 patients,
whereas no patient developed severe hypotension or required further
antiarrhythmic therapy (Table 3
).
|
| Discussion |
|---|
|
|
|---|
In animal models with both focal and global ischemia, moderate hypothermia reduced secondary brain injury and infarction size and improved neurological outcome.2 3 4 5 6 However, most of these studies used a narrow time window, with hypothermia initiated within 60 to 90 minutes after induction of experimental ischemia. Markarian et al28 demonstrated the best results in a focal ischemia model when hypothermia was applied within the first 30 minutes and lasted 3 hours. Applying these data to clinical practice would suggest that induced hypothermia is beneficial only in the very first few hours after stroke onset.
Several neurosurgical studies showed a positive effect of mild hypothermia on uncontrollable intracranial hypertension after severe head trauma.13 14 15 16 Head-injured patients treated with mild hypothermia between 32°C and 34°C core temperature had a significant reduction in ICP and cerebral blood flow compared with the normothermia-treated control group. All studies indicated better outcome with hypothermia and a beneficial effect in limiting secondary brain injury. In most of these studies, hypothermia was delivered within the first 6 to 16 hours after head injury. Duration of hypothermia varied from 24 to 48 hours, whereas neither the optimal duration of hypothermia nor the optimal time after the trauma for therapy in these patients could be identified.
Similar to these clinical studies, hypothermia was induced in this study a mean of 14 hours after the ischemic injury. Obviously, this time delay has to be reduced in further trials because according to experimental data, hypothermia has the most positive effect when applied very early after cerebral ischemia. We chose a relatively long duration of hypothermia to overcome maximum brain swelling, which is known to occur between days 2 and 5 after ischemia.29 30 31 32
In space-occupying MCA infarction, outcome is fatal in most patients,
with a mortality rate of about 80% with standard
treatment.31 32 Clinically, the patients have a severe
hemispheric syndrome with head turning and eye deviation. They usually
show a rapid decline in consciousness and develop the signs of
herniation 2 to 4 days after onset of symptoms.31 32 All
patients in this study fulfilled the criteria for diagnosis of a
"malignant" MCA infarction.31 However, the mortality
rate was only 44%, and survivors reached a favorable outcome with a
mean BI of 70 (Figure 1
and Table 4
).
|
|
It is known from animal models with global ischemia and
traumatic brain injury that moderate hypothermia attenuates secondary
brain damage by reducing cerebral ischemia and
postischemic brain edema and preserving the blood-brain
barrier. Hypothermia significantly reduced the ICP, which is similar to
the results of Marion et al14 and Shiozaki et
al,16 who used hypothermic therapy in traumatic brain
injuries. With a merely unaffected mean arterial blood
pressure and increased CPP, hypothermic therapy appears to benefit
stroke patients because uncontrolled intracranial hypertension is the
main cause of death in the first week after stroke.29 30 31 32
However, rewarming the patients constantly led to a secondary increase
in ICP, which required additional ICP therapy with mannitol. In some
cases, it even exaggerated initial ICP levels. It is known that the
rewarming period is a high-risk time for brain injury because
metabolic needs may outstrip oxygen delivery at various
temperatures.33 Of the 11 patients who died, 5 had
untreatable elevation of ICP during rewarming, whereas in 6 patients,
signs of transtentorial herniation occurred with a body temperature of
33°C. The rebound increase in ICP after rewarming might suggest that
hypothermia only delays the deleterious effects caused by
ischemic injury and thus does not result in any substantial
improvement. The fact that most patients had lower ICP levels than
before induction of hypothermia speaks clearly against this hypothesis
(Figure 2
). However, rewarming
has to be considered the "critical phase" of hypothermic therapy.
This rebound after rewarming might be due to a proposed
hypermetabolic response after induced hypothermia, as it
was described after cardiopulmonary bypass
surgery.34
|
The brain temperatures of all 25 patients were consistently higher than body-core temperatures, confirming previous data that showed a significant gradient between body-core and brain temperatures in neurotrauma patients.35 36 This may be explained by the high metabolic activity of cerebral tissue with considerable production of heat.37 Another possibility is that in the early stages of infarct formation, a decrease in cerebral blood flow may result in a decreased capacity for the blood to carry off heat generated by local cerebral metabolism.
In animal studies, it was reported that toxicity from moderate hypothermia increases as the temperature is further decreased and as the duration of hypothermia is increased.38 39 In this study, we could not observe a significant increase in the occurrence of side effects between patients cooled for 48 hours and those treated for 72 hours. Hypothermia affects virtually every organ system. The extent of hypothermia is limited by ventricular ectopy and fibrillation, but this is known to occur only at temperatures <30°C.1 In the present study, pneumonia was the only severe side effect of moderate, induced hypothermia. However, impairment of pulmonary gas exchange, caused by atelectasis, is a common problem in patients who are ventilated longer. The reported incidence of pneumonia in these patients ranges from 10% to 40%.40 The risk of developing pneumonia increases when coma, trauma, or impaired airway reflexes are present at admission to the critical care unit.40 In our study, the incidence of pneumonia of 40% is comparable to these reported data and similar to the findings of Metz and colleagues,15 who observed pneumonia in 50% of their hypothermically treated patients within the first week in the intensive care unit. Other side effects of hypothermia shown in animal studies are clotting abnormalities and coagulopathy.41 42 In baboons, systemic hypothermia led to increased bleeding times.43 In humans, the enzymatic reactions of the coagulation cascade were shown to be strongly inhibited by hypothermia.44 45 However, we could not observe any severe clotting abnormalities in the hypothermia-treated patients. On the other hand, a decrease in platelet counts during the cooling period was regularly seen, with recovery only after rewarming. Also pancreatitis with high serum amylase and lipase levels was observed after hypothermic therapy. The association between hypothermia and pancreatitis is poorly understood yet.46 In our study, the pathological signs of pancreatitis with elevated levels of amylase and lipase were completely reversible after rewarming.
In conclusion, induced, moderate hypothermia can decrease ICP and may improve mortality in patients with severe postischemic brain edema. Important side effects are reduction in platelet count, increased rate of pneumonia, and elevation of serum amylase and lipase levels. Our own preliminary results suggest a beneficial effect of moderate hypothermia in the treatment of severe space-occupying MCA infarction. However, our data call for a randomized trial of hypothermia in the therapy of malignant MCA infarction. Whether early hypothermic therapy within the first 6 hours after onset of symptoms can reduce infarct size has to be clarified in further clinical trials.
| Acknowledgments |
|---|
Received May 26, 1998; revision received July 31, 1998; accepted September 22, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. P. Meloni, F. L. Mastaglia, and N. W. Knuckey Review: Therapeutic applications of hypothermia in cerebral ischaemia Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 75 - 98. [Abstract] [PDF] |
||||
![]() |
J. Varon and P. Acosta Therapeutic Hypothermia: Past, Present, and Future Chest, May 1, 2008; 133(5): 1267 - 1274. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bardutzky and S. Schwab Antiedema Therapy in Ischemic Stroke Stroke, November 1, 2007; 38(11): 3084 - 3094. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kollmar and S. Schwab Ischaemic stroke: acute management, intensive care, and future perspectives Br. J. Anaesth., July 1, 2007; 99(1): 95 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dorotta, P. Kimball-Jones, and R. Applegate II Deep hypothermia and circulatory arrest in adults. Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2007; 11(1): 66 - 76. [Abstract] [PDF] |
||||
![]() |
C. M. Gebauer, M. Knuepfer, E. Robel-Tillig, F. Pulzer, and C. Vogtmann Hemodynamics Among Neonates With Hypoxic-Ischemic Encephalopathy During Whole-Body Hypothermia and Passive Rewarming Pediatrics, March 1, 2006; 117(3): 843 - 850. [Abstract] [Full Text] [PDF] |
||||
![]() |
A D Edwards and D V Azzopardi Therapeutic hypothermia following perinatal asphyxia. Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2006; 91(2): F127 - F131. [Abstract] [Full Text] [PDF] |
||||
![]() |
Part 9: Adult Stroke Circulation, December 13, 2005; 112(24_suppl): IV-111 - IV-120. [Full Text] [PDF] |
||||
![]() |
Part 9: Stroke Circulation, November 29, 2005; 112(22_suppl): III-110 - III-104. [Full Text] [PDF] |
||||
![]() |
K. A. Boddicker, Y. Zhang, M. B. Zimmerman, L. R. Davies, and R. E. Kerber Hypothermia Improves Defibrillation Success and Resuscitation Outcomes From Ventricular Fibrillation Circulation, June 21, 2005; 111(24): 3195 - 3201. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Berger, P. Schramm, and S. Schwab Reduction of Diffusion-Weighted MRI Lesion Volume After Early Moderate Hypothermia in Ischemic Stroke Stroke, June 1, 2005; 36(6): e56 - e58. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Krieger and M. A. Yenari Therapeutic Hypothermia for Acute Ischemic Stroke: What Do Laboratory Studies Teach Us? Stroke, June 1, 2004; 35(6): 1482 - 1489. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee, K. H. Lee, D. G. Na, H. S. Byun, Y. B. Kim, Y.-M. Shon, S.-J. Cho, J. Lee, C.-S. Chung, and S.-C. Hong Multiphasic Helical Computed Tomography Predicts Subsequent Development of Severe Brain Edema in Acute Ischemic Stroke Arch Neurol, April 1, 2004; 61(4): 505 - 509. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF] |
||||
![]() |
C. Berger and S. Schwab Editorial Comment--"Malignant" or Not: Is There a Role for In Vivo Neurochemistry? Stroke, December 1, 2003; 34(12): 2914 - 2915. [Full Text] [PDF] |
||||
![]() |
C. Dohmen, B. Bosche, R. Graf, F. Staub, L. Kracht, J. Sobesky, M. Neveling, G. Brinker, and W.-D. Heiss Prediction of Malignant Course in MCA Infarction by PET and Microdialysis Stroke, September 1, 2003; 34(9): 2152 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zausinger, K. Scholler, N. Plesnila, and R. Schmid-Elsaesser Combination Drug Therapy and Mild Hypothermia After Transient Focal Cerebral Ischemia in Rats Stroke, September 1, 2003; 34(9): 2246 - 2251. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Horstmann, P. Kalb, J. Koziol, H. Gardner, and S. Wagner Profiles of Matrix Metalloproteinases, Their Inhibitors, and Laminin in Stroke Patients: Influence of Different Therapies Stroke, September 1, 2003; 34(9): 2165 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schwab and W. Hacke Surgical Decompression of Patients With Large Middle Cerebral Artery Infarcts Is Effective Stroke, September 1, 2003; 34(9): 2304 - 2305. [Full Text] [PDF] |
||||
![]() |
W. J. Mack, J. Huang, C. Winfree, G. Kim, M. Oppermann, J. Dobak, B. Inderbitzen, S. Yon, S. Popilskis, J. Lasheras, et al. Ultrarapid, Convection-Enhanced Intravascular Hypothermia: A Feasibility Study in Nonhuman Primate Stroke Stroke, August 1, 2003; 34(8): 1994 - 1999. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Doufas, A. Wadhwa, C.-M. Lin, Y. M. Shah, K. Hanni, and D. I. Sessler Neither Arm nor Face Warming Reduces the Shivering Threshold in Unanesthetized Humans Stroke, July 1, 2003; 34(7): 1736 - 1740. [Abstract] [Full Text] [PDF] |
||||
![]() |